The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Andrews Patricia S | Director | Grant(A) | 30K | — | $0 |
| Jun 1, 2026 | Aromando Andrew | Chief Business Officer | Grant(A) | 260K | — | $0 |
| Jun 1, 2026 | Brown Deborah Margaret | Director | Grant(A) | 30K | — | $0 |
| Jun 1, 2026 | Hagerman Allison | Chief Technology Officer | Grant(A) | 260K | — | $0 |
| Jun 1, 2026 | Heineman Thomas Charles | Chief Medical Officer | Grant(A) | 260K | — | $0 |
| Jun 1, 2026 | Glover Stephen C. | Director | Grant(A) | 96K | — | $0 |
| Jun 1, 2026 | Holtham Angela | Director | Grant(A) | 30K | — | $0 |
| Jun 1, 2026 | McAdory John Bearden | Chief Operating Officer | Grant(A) | 145K | — | $0 |
| Jun 1, 2026 | Kelly Jared | Chief Executive Officer, Director | Grant(A) | 755K | — | $0 |
| Jun 1, 2026 | Seizinger Bernd R. | Director | Grant(A) | 30K | — | $0 |
| Jun 1, 2026 | Parsons James T. | Director | Grant(A) | 30K | — | $0 |
| Jun 1, 2026 | Pisano Wayne | Director | Grant(A) | 30K | — | $0 |
| Jun 1, 2026 | Rigby Jonathan | Director | Grant(A) | 30K | — | $0 |
| Jun 1, 2026 | Look Kirk | Chief Financial Officer | Grant(A) | 260K | — | $0 |
| Mar 12, 2026 | Kelly Jared | Chief Executive Officer, Director | Buy(P) | 5K | $0.96 | $5K |
| Mar 11, 2026 | Parsons James T. | Director | Buy(P) | 10K | $1.03 | $10K |
| Feb 12, 2026 | Andrews Patricia S | Director | Buy(P) | 35K | $0.86 | $30K |
| Feb 12, 2026 | Brown Deborah Margaret | Director | Buy(P) | 25K | $0.85 | $21K |
| Feb 12, 2026 | Hagerman Allison | VP, Product Development | Buy(P) | 10K | $0.83 | $8K |
| Feb 12, 2026 | Heineman Thomas Charles | Chief Medical Officer | Buy(P) | 12K | $0.83 | $10K |
| Feb 12, 2026 | Kelly Jared | Chief Executive Officer, Director | Buy(P) | 30K | $0.84 | $25K |
| Feb 12, 2026 | Look Kirk | Chief Financial Officer | Buy(P) | 12K | $0.84 | $10K |
| Feb 12, 2026 | Pisano Wayne | Director | Buy(P) | 30K | $0.84 | $25K |
| Feb 12, 2026 | Seizinger Bernd R. | Director | Buy(P) | 40K | $0.85 | $34K |
| Feb 11, 2026 | Aromando Andrew | Chief Business Officer | Buy(P) | 30K | $0.86 | $25K |
| Feb 11, 2026 | Kelly Jared | Chief Executive Officer, Director | Buy(P) | 6K | $0.84 | $5K |
| Feb 11, 2026 | Seizinger Bernd R. | Director | Buy(P) | 60K | $0.83 | $50K |
| Jan 16, 2026 | Seizinger Bernd R. | Director | Buy(P) | 100K | $1.04 | $104K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Oncolytics Biotech Inc, SEC CIK 0001129928. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under ONCY and shows every filing by that issuer.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-15. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for ONCY